|

Pegylated liposomal Doxorubicin (PLD) Clinical Trials

5 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Also known as: Doxil; Caelyx, Doxorubicin Hydrochloride Liposome Injection, duomeisu

Pipeline

Phase 3: 5

Top Sponsors

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • GlaxoSmithKline1
  • Genmab1
  • Eli Lilly and Company1
  • AstraZeneca1

Indications

  • Cancer5
  • Ovarian Neoplasms2
  • Peritoneal Neoplasms1
  • Platinum-resistant Ovarian Cancer1
  • Fallopian Tube Neoplasms1

Other3 trials

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Phase 3
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
Phase 3
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Phase 3

Birmingham, Alabama2 trials

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

University of Alabama at Birmingham

Phase 3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Research Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.